Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof

US9073939B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Martin Michels
• Markus Follmann
• Alexandros Vakalopoulos · Hilden, DE
• Katja Zimmermann · Mülheim an der Ruhr, DE
• Nicole Teusch · Uerdingen, DE
• Mario Lobell · Wuppertal, DE

Key dates

• Filing date: Jul 7, 2010
• Grant date: Jul 7, 2015
• Expiry date: Feb 11, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to novel 4-(indazol-5-yl)-4,7-dihydroisoxazolo[5,4-b]pyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.